Recently, it has been shown that brusatol, an inhibitor of Nrf2 pathway, markedly decreases the Nrf2 level,49, 50 while it enhances intracellular ROS and sensitizes tumor cells to chemotherapeutic drugs. Here, NFE2L2 is linked to neoplasm.